市場調查報告書
商品編碼
1535117
全球腎神經阻斷導管市場 - 市場規模(依細分市場)、佔有率、監管、償付、程序、預測(至2033年)Renal Denervation Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球高血壓流行是腎神經阻斷導管市場的最大驅動因素之一。高血壓通常可以透過改變生活型態和處方藥物來控制,但有時即使使用三種或更多抗高血壓藥物(包括利尿劑)也無法達到血壓目標。此類病例稱為頑固性高血壓。如果不及時治療,可能會導致多種併發症。據觀察,頑固性高血壓與交感神經系統的慢性活化有關。該藥可以透過減少交感傳入和傳出腎神經的活動來降低血壓。腎去神經術是一種短期、長期治療方法,可為難治性高血壓患者提供替代治療。
本報告研究和分析了全球腎神經阻斷導管市場,提供了有關主要參與者和市場佔有率、主要趨勢、創新產品和技術以及競爭格局的資訊。
市場模型的主要內容如下。
已上市的腎神經阻斷導管和不斷變化的競爭格局
全球、區域和國家層面的特定市場考察
透過對醫療保健系統的真實、全面的了解來促進市場理解。市場進入部分還提供有關償付政策和監管環境的訊息,能夠更深入地研究市場動態。
目標公司
Renal Denervation Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative and qualitative market trends within Cardiovascular Devices therapeutic area.
Renal denervation, also known as renal sympathetic denervation (RSD), is a minimally invasive, catheter-based endovascular procedure that utilizes radiofrequency energy or ultrasound energy to ablate nerves in the walls of the renal artery, causing a reduction in the nerve activity which ultimately reduces the blood pressure in patients with resistant hypertension.
The global prevalence of hypertension is one of the largest drivers in the renal denervation market. While hypertension can usually be controlled with lifestyle modifications and taking medications as prescribed, there are cases where the target blood pressure cannot be achieved even with three or more antihypertensive drugs (including a diuretic). Such cases are termed resistant hypertensive cases. If left untreated, several comorbidities can result. It has been observed that resistant hypertension can be associated with chronic activation of the sympathetic nervous system. By reducing the activity of sympathetic afferent and efferent renal nerves, it may be possible to lower blood pressure. Renal denervation is a quick and potentially long-lasting treatment option and has the potential to provide an alternative therapeutic approach for patients suffering from resistant hypertension.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Renal Denervation Catheters and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Medtronic Plc, Boston Scientific Corp, Abbott laboratories, ReCor Medical Inc, and Others.
Countries covered: United States, Canada, Mexico, France, Germany, Italy, Spain, United Kingdom, Russia, Austria, Greece, Sweden, Switzerland, Australia, China, India, Japan, South Korea, Brazil, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -